The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced the reclassification of Nasonex mometasone furoate nasal spray from a “POM,” or “prescription only medicine,” to a “P” medicine, available over the counter at pharmacies with pharmacist supervision. The product is approved for the treatment of allergic rhinitis.
Bayer, which acquired Merck’s Consumer Care division in 2014, submitted the application for reclassification, and the MHRA posted a request for public comments in November 2016. Responses from organizations including the Royal Pharmaceutical Society, the Guild of Healthcare Pharmacists, and the Royal College of Physicians supported reclassification.
The OTC version of the nasal spray, which will be marketed as Nasonex Allergy Control, will be the first mometasone furoate product available over the counter in the UK.
Read the MHRA announcement.
Read the MHRA consultation documents.
